IMMUNOVANT, INC. — Earnings
Most recent reported period: FY2024 (Q1) (filed for period ending 2024-03-31) · sourced from SEC EDGAR
Next earnings (estimated): Sun, June 30, 2024 — 673 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | — | — | $-111M | ↑+0.4% | — |
| 2025-09-30 | — | — | $-127M | ↓-15.9% | — |
| 2025-06-30 | — | — | $-121M | ↓-38.4% | — |
| 2025-03-31 | — | — | — | — | — |
| 2024-12-31 | — | — | $-111M | ↓-116.1% | — |
| 2024-09-30 | — | — | $-109M | ↓-86.0% | — |
| 2024-06-30 | — | — | $-87M | ↓-17.9% | — |
| 2024-03-31 | $8M | ↑+140.8% | — | — | — |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2024 (Q1)
Revenue
$8M
↑+140.8% +$5M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
IMVT Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyIMVT Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics